Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807411 | 0.88 | ALDH1A1 (0.52) | TTRMAOACYP3A4MAPTSMN1; SMN2 | |
| SCHEMBL10932722 | 0.86 | MAOA (0.54) | TTRMAOAMAOBCYP3A4LMNA | |
| SCHEMBL2941282 | 0.85 | MEN1 (0.48) | TTRCYP3A4MEN1KMT2A | |
| SCHEMBL1347657 | 0.83 | CASP1 (0.50) | TTRCYP3A4LMNATP53ADORA3 | |
| SCHEMBL13068903 | 0.82 | NCOA1 (0.56) | TTRMAOAMAOBCYP3A4LMNA | |
| SCHEMBL19990170 | 0.80 | MAOA (0.56) | TTRMAOAMAOBCYP3A4MAPT | |
| SCHEMBL4958922 | 0.80 | TTR (0.65) | TTRMAOBMEN1KMT2A | |
| SCHEMBL9645412 | 0.80 | TTR (0.65) | TTRLMNAMAPTMEN1KMT2A | |
| SCHEMBL29382755 | 0.80 | CYP1A2 (0.67) | MAOAMAOBCYP3A4LMNAMAPT | |
| SCHEMBL3114464 | 0.80 | CYP1A2 (0.67) | MAOAMAOBCYP3A4LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513032-B | 4-Substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | AlzeCure Pharma AB (SE) | 2023-12-12 | — | — | US | disclosed |
| EP-3814335-B1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2022-11-09 | — | — | EP | disclosed |
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2022-10-13 | — | — | US | disclosed |
| EP-4021573-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | Alzecure Pharma AB (SE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114423743-A | Triazine derivatives for the treatment of diseases associated with neurotrophic factors | 阿泽克制药公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | AlzeCure Pharma AB (SE) | 2021-12-02 | — | — | US | disclosed |
| EP-3814335-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | Alzecure Pharma AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513032-A | 4-substituted phenyl-1, 3, 5-triazine derivatives as modulators of TRK receptors | 阿泽克制药公司 | 2021-03-16 | — | — | CN | disclosed |
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021038241-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | AlzeCure Pharma AB (SE) | 2021-03-04 | — | — | WO | disclosed |
| EP-1147093-B1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2007-04-11 | — | — | EP | disclosed |
| CN-1182123-C | Substituted bicyclic derivatives useful as anticancer agents | �Ʒ� | 2004-12-29 | — | — | CN | disclosed |
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| US-6541481-B2 | A quinazoline compound | PFIZER INC | 2003-04-01 | — | — | US | disclosed |
| CN-1333758-A | Substituted bicyclic derivatives useful as anticancer agents | PFIZER PROD INC (US) | 2002-01-30 | — | — | CN | disclosed |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | KATH JOHN CHARLES (US) | 2001-10-25 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186995-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | TTR 4598/4885MAOA 2918/4885MAOB 2762/4885 |
| US-11840524-B2 | 4-substituted phenyl-1,3,5-triazine derivatives as modulators of TrK receptors | NTRK2, NTRK3, BDNF | TTR 641/4885MAOA 533/4885MAOB 894/4885 |
| US-20220324819-A1 | TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS | NTRK2, BDNF, NGF | TTR 1488/4885MAOA 162/4885MAOB 198/4885 |
| US-20010034351-A1 | Substituted bicyclic derivatives useful as anticancer agents | CCNA1, MCL1, RCC1 | TTR 4598/4885MAOA 2918/4885MAOB 2762/4885 |
| US-20210371402-A1 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS | NTRK2, NTRK3, BDNF | TTR 641/4885MAOA 533/4885MAOB 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.